Serendex Pharmaceut​icals A/S

Serendex skal på noteres på Oslo Axess. Selskapet frontes av Norne Securities med støtte i fra Netfonds. Det tilbys en retail rabatt på 1.500 og minste tegningsbeløp er 10.500. Tegningsfristen er 20.06.2014 kl. 12.00.

Om businessen:
Serendex is a pharmaceutical company dedicated to the development of new, effective treatments for serious lung diseases that do not respond to best current therapeutic practice. By repositioning well-nown, existing drugs that have a limited use within their current indications, Serendex seeks to meet this medical need. The current pipeline focuses on the following seven indications:
• Molgradex® for the treatment of pulmonary alveolar proteinosis (PAP)
• Molgradex® for the treatment of cystic fibrosis (CF) lung infections
• Molgradex® for the treatment of lung infections in non-cystic-fibrosis bronchiectasis (BE)
• Molgradex® for the treatment of acute respiratory distress syndrome (ARDS) and ventilator-requiring lung infection (“VAP”)
• APC: recombinant human activated protein C OR TFPI: recombinant human tissue factor pathway inhibitor for the treatment of acute respiratory distress syndrome (ARDS) and acute lung injury (ALI)
• FVIIa: recombinant human factor VIIa (eptacog alfa (activated)) for the treatment of diffuse alveolar hemorrhage (DAH)
• Fosfomycin: inhaled fosfomycin for the treatment of lung infections with antibiotic-resistant organisms.

Prospekt:
http://www.netfonds.no/tegning.php?page=SERE-PRO

Selskapet:
http://www.serendex.com/